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ABSTRACT
Objectives: The subjects in the Sleman District of Yogyakarta had medium Framingham risk score (FRS) in the preceding year study. The 10-year 
atherosclerotic cardiovascular disease (ASCVD) risk was a newer risk estimator than FRS. This study aimed to associate the lipid profiles with the 
ASCVD risk.
Methods: The study was conducted with a cross-sectional design and the subjects were selected with cluster random sampling. The association of 
lipid profiles and ASCVD risk was analyzed with Mann–Whitney/Kruskal–Wallis tests and Spearman’s rho correlation, whereas the categorical scores 
within sub-groups were analyzed Chi-square statistics, respectively.
Results: The eligible subjects (n=221) had the age at 51.7±8.1 years, systolic/diastolic blood pressure 136.8±22.4/85.0±12.4 mmHg, total-cholesterol 
(total-C), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglyceride at 202.0±34.9 mg/dl, 
52.6±12.5 mg/dl, 126.3±30.0 mg/dl, and 135.9±95.4 mg/dl, respectively; with hypertension treatment 16.7%, smoking 52.9%, diabetes 10.4%, and 
the median ASCVD risk at 4.4 (0.2-41.4). The ASCVD risk has  significant association with non-lipid profiles, total-C, lipid ratio of triglyceride/HDL-C, 
total-C/HDL-C, and LDL-C/HDL-C,  to a lesser extent, HDL-C, LDL-C, and triglyceride.
Conclusion: The 10-year ASCVD risk of the subjects was categorized as low and had a significant association with total-C and lipid ratio of triglyceride/
HDL-C, total-C/HDL-C, and LDL-C/HDL-C.
Keywords: Atherosclerotic cardiovascular disease, 10-year atherosclerotic cardiovascular disease risk, lipid profiles, cholesterol, ratio total-
cholesterol/high-density lipoprotein-cholesterol-C, ratio low-density lipoprotein-cholesterol/high-density lipoprotein-cholesterol.
INTRODUCTION
Cardiovascular diseases (CVDs) cause the global highest mortality 
rate [1]. The CVDs are caused by the cumulative risk factors including 
obesity, hypertension, hypercholesterolemia, diabetes mellitus (DM), 
smoking, unhealthy lifestyle, race, and education [2,3]. A newer guideline 
on the hypercholesterolemia treatment to reduce “atherosclerosis 
cardiovascular risk in adults (atherosclerotic cardiovascular disease 
[ASCVD])” was introduced in the year 2013 by American College of 
Cardiology/American Heart Association (ACC/AHA). In the conventional 
guideline, the total-cholesterol (total-C) levels at <200 mg/dl and 
≥240 mg/dl were categorized as desirable and high, respectively;  the 
high-density lipoprotein-cholesterol (HDL-C) levels at <40 mg/dl and 
>60 mg/dl were categorized as low and high; and the low-density 
lipoprotein-cholesterol (LDL-C) levels at <100 mg/dl and >160 mg/dl 
as were as ideal high [4]. The newer guideline is substantially different 
from the conventional one because the guideline did not provide the 
exact cholesterol cut point for CVDs [5].
A terminology of ASCVD replaced the established term of CVD [5]. The 
10-year ASCVD risk for the first cardiovascular event in percentage 
could be predicted with several methods, e.g., systemic coronary risk 
estimation (SCORE) used among European countries, Framingham 
risk score (FRS), pooled cohort equation (PCE) with the 10-year 
ASCVD risk, and some other methods [6,7]. The ASCVD risk showed 
moderate discrimination and good calibration in an Asian population. 
The moderate discrimination due to the high prevalence of ASCVD risk 
factors was improved with clustering of higher risk patients, whereas 
fewer patients were needed among the patients with lower risk [8]. 
Therefore in a general population of subjects with a wider range of 
ASCVD risk, the risk prediction using PCE method may give a better 
discrimination [8,9].
The 10-year ASCVD risk of PCE was obtained from four pooled cohort 
prospective studies including Framingham studies both original and 
derivative studies with >20,000 subjects aged at 20-79 years [2]. The 
PCE estimates the hard risk of ASCVD including myocardial infarction, 
coronary hard disease death, nonfatal, and fatal stroke [6,10].
In the 2013 ACC/AHA Guideline, the initiation and continuing 
treatment for hypercholesterolemia was determined by the 10-year 
ASCVD risk score, the existence of DM, and LDL-C level. Furthermore, a 
statin was the only beneficial medication for the hard ASCVD reduction 
in hypercholesterolemia in the guideline [5,6]. The conventional 
FRS method has the cardiovascular risk classification of >20 (high), 
10-20 (moderate), and <10 (low) of 10-year risk [4], while the 10-year 
ASCVD risk has  the classification as  follow: <5, 5-<7.5, ≥7.5-<10, and 
≥10  as  low,  moderate,  high,  and  very  high  risk,  respectively  [11]. 
While the 10-year ASCVD risk was implemented in the screening of 
the four statin-favored subjects, the risk was only classified into three 
categories, i.e., <5, 5-<7.5, ≥7.5 as low, moderate, and high risk. The four 
statin-favored subjects consist of (1) clinical atherosclerosis, (2) DM, 
(3) LDL-C higher than 190 mg/dl, and (4) subjects without DM or 
ASCVD but with ≥7.5 of 10-year ASCVD risk [5,9].
The subjects in the Sleman District (n=926) in the year 2015 were 
reported to be high prevalence of hypertension but with low awareness 
and therapy of the disease [12], meanwhile from the study conducted 
in the district in the year 2016, the subjects (n=222) had the FRS at 
11.4±8.9, and classified as medium risk [13]. There was no information 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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regarding the 10-year ASCVD risk using PCE method found among 
the population in Sleman District. This study aimed to investigate the 
10-year ASCVD risk using the PCE method and to associate the ASCVD 
risk score with the lipid profile of the subjects.
METHODS
This study was the year two survey with the focus on the therapeutic 
lifestyle changes among the subjects in Sleman District. The study was 
an observational research conducted with analytical cross-sectional 
design. The sites of study were selected with stratified random 
sampling. The protocol has been approved with the ethical clearance 
Ref No: KE/FK/043/EC/2016 by Ethics Committee of Gadjah Mada 
University, Yogyakarta. The preceding year study has been published 
as: “The Metabolic Disorder and Cardiovascular Risk among Lower 
Socioeconomic Subjects” [13]. The FRS risk score from the preceding 
year study was not compared with the ASCVD risk from this study. The 
subjects between studies were different because the excluded subjects 
from year one due to the failure of meal fasting were invited as the 
subjects of the year two study. Moreover, the FRS method includes a 
wider range of age and total-C than the ASCVD risk and covers more 
subjects accordingly. Data in year two were added with LDL-cholesterol 
and triglyceride measurement.
The subjects were selected with cluster random sampling from the 
study sites. All subjects met the criteria of 10-year ASCVD risk were 
included. The criteria of PCE method included gender (male and 
female), age within 40-79 years old, HDL-C within20-100 mg/dl, total-C 
at 130-320 mg/dl, systolic blood pressure (SBP) within 90-200 mmHg, 
race (white, African-American, or others), diabetes (yes, no), treatment 
for hypertension (yes, no), and smoker (yes, no). Exclusion criteria in 
year one study covered the subjects with hard ASCVD and/or failed to 
proceed the 8-10 hrs meal fasting.
Analysis
The ASCVD risk calculator from PCE method is available online for two 
types of ASCVD risks, i.e.: 10-year risk for subjects at the age 40-79 years 
and lifetime ASCVD risk for the age at 30-60 years [9]. The study focused 
more on 10-year ASCVD risk of the 236 eligible participants for PCE at 
the age of 30-75 years; there were 15 subjects could not be calculated 
due to the age <40 years old, but they were included in the lifetime 
ASCVD risk score calculation. The cut point of the lipid profile used the 
standard of the National Cholesterol Education Program Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III) guideline [4].
Before the evaluation of the variable association, the data were 
analyzed for the normality of data distribution and the body mass 
index (BMI) was the only normally distributed variable. The subgroup 
difference of the 10-year ASCVD risk within a variable was analyzed 
with Mann–Whitney U-test or with Kruskal–Wallis test due to the data 
distribution. The association of 10-year ASCVD risk in categorical 
risk with the lipid profile in categorical risk was analyzed with 2×2 
Chi-square test. The lowest cut point sub-group in each variable 
was determined as a control group. In the Chi-square analysis, the 
10-year ASCVD risk was grouped into two classifications, i.e., lower 
risk  at  <7.5  and  higher  risk  at  ≥7.5  ASCVD  risk.  The  variables  of 
PCE method were correlated with the ASCVD risk score using the 
Spearman’s Correlation analysis, and the coefficients (rho or r) at 
<0.3, ≥0.3-<0.7,  and ≥0.7 were  categorized as weak, moderate,  and 
strong correlation [14].
RESULTS
Of the total subjects (n=236), the eligible subjects for 10-year ASCVD 
risk were 221 respondents, whereas the eligible subjects for lifetime 
risk method were 182 respondents. The study focused only the 10-year 
ASCVD risk in the further discussion. The median 10-year ASCVD risk 
score was at 4.4% and classified as low-risk (<5 score), and the risk 
classified the subjects into four levels of risk, i.e., low, moderate, and 
Table 1: Characteristics of cardiovascular risk and lipid profiles
Characteristics of cardiovascular 





Age (years old) 51.7±8.1
51 (40-73)
Systolic blood pressure or SBP (mmHg) 136.8±22.4
133 (101-200)






Body mass index or BMI kg/m2* 24.2±4.5*
24.1 (14.2-41.4)
Fasting blood glucose or FBG (mg/dl) 98.1±50.0
85 (59-565)








Triglyceride or TG (mg/dl) 135.9±95.4
109 (43-1018)
Ratio TG/HDL (mg/dl) 3.0±2.9
2.2 (0.5-29.1)
Ratio LDL/HDL (mg/dl) 2.5±0.9
2.6 (1.0-7.1)
Ratio total-cholesterol/HDL (mg/dl) 4.1±1.2
3.9 (2.0-10.3)
*Data: Normally distributed. ASCVD: Atherosclerotic cardiovascular disease, 
HDL: High-density lipoprotein, LDL: Low-density lipoprotein, SD: Standard 
deviation
high-risk subjects [11], and most subjects were in the low-risk. Although 
most of the subjects had low ASCVD risk, overall there 81 subjects 
(36.7%) needed statin according to guideline. The statin was needed 
for the DM subjects (n=23) distributed into low-risk (n=9), moderate 
risk (n=4), and high-risk (n=14), and among those without DM (n=58) 
but with ≥7.5 ASCVD risk (Fig. 1) [5].
The subject characteristics were not normally distributed except for 
BMI, and the data were presented as median value. The subjects had 
relatively young age at median 51 years. The subject characteristics 
including SBP/diastolic blood pressure (DBP), pulse, blood glucose, 
and lipid profiles showed the near ideal to borderline median values 
(Table 1).
The parameter of ASCVD variables, i.e., gender, treatment for 
hypertension, DM, smoking, age, systolic blood pressure (SBP), and 
BMI was classified into the subgroups based on the categorical risk. The 
lowest cut point subgroup in each variable acted as the control group. 
The result showed the association all estimators with the 10-year ASCVD 
risk significantly (p<0.05) with Mann–Whitney/Kruskal–Wallis test. The 
ASCVD risk was not associated with BMI (p=0.60). The increased risk in 
each variable showed the increased odds ratio related to ASCVD risk, 
i.e., in male, older age, higher SBP, the existence of DM, and hypertension 
treatment, but excluding the smoking and BMI variables.
The correlation between the ASCVD and the ASCVD variables plus BMI 
was done using the Spearman’s test. The BMI was not belonged to the 
ASCVD variables, but it was included in the analysis because BMI is an 
ASCVD risk in general population. The age variable had the strongest 
correlation with the ASCVD risk followed by the SBP with moderate 
correlation. The variable of age had the strongest correlation with 
ASCVD at moderate intensity (r=0.67) with the ASCVD risk among all 
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variables of lipid or non-lipid profiles, and the correlation with SBP 
was at the second highest, the correlation with smoking, and gender 
variables; out of these four variables the other variables had the weak 
correlation (Table 2).
Similar to non-lipid profiles, the categorical lipid profiles were 
significantly different using the Kruskal–Wallis test (p<0.01). The higher 
total-C in categorical classification had the higher ASCVD risk, whereas 
the lowest HDL-C sub-group has the highest ASCVD risk (p<0.05). The 
total-C, ratio of triglyceride/HDL-C, total-C/HDL-C, and LDL-C/HDL-C 
had significantly different of 10-year ASCVD risk in Mann–Whitney 
test in all sub-groups, whereas the HDL-C, LDL-C, and triglyceride had 
significantly different of risk in some sub-groups. The two lowest sub-
groups of LDL-C; HDL-C; and total-C had not-significantly different 
10-year ASCVD risk within the variables. All lipid profile had a weak 
correlation with 10-year ASCVD risk (Table 3).
DISCUSSION
The finding of the low 10-year ASCVD risk this study was different from 
the previous year result using the FRS method in the moderate risk [13]. 
The difference was likely caused by the inclusion of subjects. The ASCVD 
risk of the PCE could not comprehensively include all subjects from 
FRS method. The ASCVD risk method was limited for the subjects with 
40-79 years, total-C of 130-320 mg/dl, and HDL-C of 20-100 mg/dl [3,9].
In this study, all subjects in the cluster were invited, and the subjects 
in the subgroups could not be matched for all of the nine variables in 
10-year ASCVD risk, e.g., fewer male, DM, and with therapy subjects. 
In general population, the ASCVD risk is higher in male than female 
subjects, though the gender risk difference diminished in the elderly 
subjects [15], the ASCVD risk is also higher among DM and/or with 
hypertension therapy [9]. The similar findings from this study showed 
that the male, DM, and/or with hypertension therapy subjects had a 
significantly higher risk.
The low ASCVD risk was likely related to the subjects’ age because 
the age had the strongest correlation to the ASCVD risk among other 
variables. The ASCVD risk in this study had much higher correlation 
than the FRS and age correlation found in a study done among the 
outpatients found in Baghdad with r=0.296 [16].
The median age of the subjects at 51 years was younger than the 
age with ASCVD risk at 55 years. The ASCVD history occurred at 
<55 and <65 years for male and female, respectively, was defined as 
Table 2: Distribution of the 10‑year ASCVD using risk pooled cohort equation risk estimators for the cardiovascular disease‑related 
variables
Characteristics 10‑year CVD risk 
Mean±SD
p value*1 Spearman’s rho (r) 
correlation*2
Proportion n (%) OR (CI 95%)*3
Gender
Male 12.8±9.3 - −0.34 52 (23.5) 1.0
Female 5.5±5.7 p<0.01 169 (76.50 0.18 (0.10-0.35)
Hypertension treatment
Yes 12.5±9.1 - −0.27 37 (16.7) 1.0
No 6.2±6.5 p<0.01 184 (83.3) 0.2 (0.1-0.4)
Diabetes mellitus
Yes 14.9±11.7 - −0.20 23 (10.4) 1.0
No 6.4±6.1 p<0.01 198 (83.3) 0.3 (0.1-0.6)
Smoking
Yes 9.5±8.2 - −0.21 117 (52.9) 1.0
No 4.8±5.2 p<0.01 104 (47.1) 0.57 (0.32-1.00)
Age*4
≤50 years 3.5±4.2 - 0.67 117 (52.9) 1.0
>50 years 10.7±7.9 p<0.01 104 (47.1) 15.1 (7.0-32.6)
Systolic blood pressure
<140 mmHg 4.2±4.1 - 0.53 133 (60.2) 1.0
140-<160 mmHg 10.0±6.3 p<0.01 52 (23.5) 6.5 (3.2-13.4)
160-<180 mmHg 13.8±8.5 p<0.01 26 (11.8) 22.5 (8.0-63.0)
≥180 mmHg 16.4±11.1 p<0.01 10 (4.5) 15.7 (3.7-66.1)
BMI*4
<24.3 kg/m2 6.7±6.2 - −0.03 110 (49.8) 1.0
≥24.3 kg/m2 7.9±8.3 p=0.60 111 (50.2) 1.06 (0.61-1.84)
CVD: Cardiovascular disease; 10-year risk in percentage (%). *1p value: Mann–Whitney/Kruskal–Wallis for 2 or 3 sub-group variables. p value compared with the 
lowest cut point sub-group. *2Correlation of the variables with 10-year ASCVD risk. *3OR (95% CI): Odds ratio (95% confidence interval); OR compared with the lowest 
cut point sub-group. *4Age and BMI sub-group cut point based on median value. BMI: Body mass index, ASCVD: Atherosclerotic cardiovascular disease, SD: Standard 
deviation
Subjects (n) 221 182
Age mean±SD years 51.7±8.1 47.0±6.7
Median age (min-max) years 51 (40-73) 47 (30-58)
Mean risk±SD (%) 7.3±7.4 42.1±54.5
Median risk % (min-max) 4.4 (0.2-41.4) 39 (5-69)
10-year ASCVD score*
Low risk <5 56.1 n.a.
Moderate risk 5-7.5 18.1
High risk >7.5 32.6
(Including very high risk >10) (24.9)
Fig. 1: The subjects distribution with 10‑year risk score 
and lifetime risk score using pooled cohort equation 
method. *Diabetes mellitus (DM) comorbid subjects (n=27): 
Atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5 
(n=14); >5‑<7.5 (n=4); <5 (n=9); without DM (n=58) but with 
≥7.5 ASCVD risk
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premature ASCVD [17]. The finding from the previous study in the 
area showed the older age of the subjects had the more ASCVD risk 
factors [13]. The subjects in this study had the high level of BMI, and 
it is likely the signal of early ASCVD, higher risk of DM, hypertension, 
and hypercholesterolemia [18]. An investigation done in urban India 
showed that the earlier escalation of ASCVD risk factors at the younger 
age of 30-39 year [19]. The subjects in this study were from rural area, 
and the subject’s environment was likely the secondary reason for the 
relatively low ASCVD risk.
The ASCVD risk indicated a higher proportion of subjects eligible for 
statin than another method [3]. It was found in the study that high 
proportion of subjects needed for statin. The finding was similar to 
the study done in Denmark with 42% subjects eligible for statin using 
the ASCVD risk score and only 6% with the ESC/EAS guideline [20]. 
There was disagreement regarding the higher proportion of eligible 
for statin subjects based on ASCVD risk. A study criticized, the ASCVD 
caused the increased statin prescription frequency to subjects [10], 
whereas the other study supported the more statins based on 
ASCVD [2]. Furthermore, a study recommended the therapeutic 
lifestyle modification and/or pharmacology intervention reduce the 
atherosclerosis and suggested the preventive activities were cost-
effectiveness among subjects with or without DM [21]. Study in India 
showed the increase of physical activities with telephone counseling 
intervention in DM subjects [22]. Lifestyle modification should be 
considered as one method that could prevent ASCVD.
The subjects in this study had low awareness, and also did not initiate 
or continue the treatment with statin. This condition was likely related 
to the subjects’ profile, i.e., low educational background discussed in 
the preceding study [13].
The prevalence of smoking, DM, SBP≥140 mmHg was at 52.9%, 10.4%, 
and 39.8%, respectively, and could be considered as high prevalence. 
Besides the BMI variable, all other non-lipid variables showed that 
higher risk of the subjects had the higher ASCVD risk. The subjects 
without hypertension therapy were considered lower risk and with 
significantly lower ASCVD risk. Most subjects had the inadequate 
therapy to control the high blood pressure or hypercholesterolemia the 
finding was not improved from the previous study [12,13]. The subjects 
were likely need pharmacology therapy. Atorvastatin and irbesartan in 
fixed-dose combination might be recommended for the patients with 
CVD with hyperlipidemias and hypertension. Both of medicines could 
increase endothelial function and reduce inflammatory [23].
Although the triglyceride was not belonged to one of the ASCVD 
variables, the 10-year risk of ASCDV had a significant association with 
triglyceride and ratio triglyceride/HDL-C. Many experts considered 
single parameter of lipid profile had better correlation with ASCVD, but 
a study showed that high ratio of triglycerides to HDL-C was likely to 
predict the existence of coronary heart disease [24].
The subjects in this study were Asian (non-White or non-African race 
100%) population, in the ASCVD risk method the Asian subjects were 
categorized as other than white and African. During the writing process 
of this study, there is no reference of the ASCVD risk information for 
Indonesian subjects. According to a reference, the ASCVD risk method 
appeared to overestimate absolute ASCVD risk as the observed events 
were less than predicted [8]. A similar finding in an external calibration 
on ASCVD risk, the result showed that the method in 15 cohort studies, 
reanalyzed studies, or external calibration overestimated the ASCVD 
risk in almost all studies. The studies included one cohort done among 
Malaysian whose population had similar genetics to Indonesian 
Table 3: Distribution of the 10‑year ASCVD using risk pooled cohort equation risk estimators for lipid profiles




Spearman’s rho (r)*2 
correlation
Proportion n (%) OR (CI 95%)*3
Total-C (mg/dl)
<200 (low) 5.4±6.2 - 0.26 117 (52.9) 1.0
200-239 (moderate) 8.6±7.9 p<0.01 71 (32.1) 3.1 (1.6-6.0)
≥240 (high) 10.7±8.2 p<0.01 (p<0.01) 33 (14.9) 6.3 (1.3-14.3)
HDL-C (mg/dl)
<40 (low) 9.2±9.4 - −0.23 26 (11.8) 1.0
40-60 (moderate) 7.8±7.5 p=0.53 150 (67.9) 0.8 (0.4-1.9)
>60 (high) 4.2±4.3 p=0.03 (p<0.01) 45 (20.4) 0.4 (0.1-1.2)
LDL-C (mg/dl)
<100 (normal) 5.6±5.8 - 0.19 40 (18.1) 1.0
100-129 (near normal) 6.3±7.3 p=0.57 85 (38.5) 0.7 (0.3-1.6)
130-159 (borderline high) 8.5±6.8 p=0.02 54 (24.4) 1.7 (0.7-4.1)
160-189 (high) 9.4±9.4 p=0.03 24 (10.9) 1.8 (0.6-5.3)
>190 (very high) 14.9±10.5 p=0.01 (p<0.01) 6 (2.7) 5.2 (0.8-32.0)
Triglyceride (mg/dl)
<150 (normal) 6.0±6.5 - 0.35 148 (67.0) 1.0
150-199 (borderline high) 8.3±6.3 p=0.13 27 (12.2) 2.7 (1.2-6.2)
200-499 (high) 12.4±9.7 p<0.01 33 (14.9) 5.1 (2.3-11.2)
≥500 (very high) n.a. n.a. (p<0.01) 1 (0.5) n.a.
Ratio triglyceride/HDL-C
<2 (ideal) 4.6±5.0 - 0.35 90 (40.7) 1.0
2-<4 (preferable) 8.5±7.6 p<0.01 78 (35.3) 3.0 (1.5-6.2)
≥4 (high risk) 11.3±9.2 p<0.01 (p<0.01) 41 (18.6) 6.5 (2.9-14.6)
Ratio total-C/HDL-C
<3.5 (ideal) 5.0±5.3 - 0.35 79 (35.7) 1.0
3.5-<5 (preferable) 7.3±7.5 p=0.01 102 (46.2) 1.2 (0.6-2.3)
≥5 (high risk) 11.8±8.4 p<0.01 (p<0.01) 40 (18.1) 4.8 (2.2-10.4)
Ratio LDL-C/HDL-C
<2.5 (ideal) 5.3±5.4 - 0.29 98 (44.3) 1.0
2.5-3.5 (preferable) 7.6±7.0 p=0.01 85 (38.5) 1.6 (0.8-3.0)
≥3.5 (high) 14.5±10.5 p<0.01 (p<0.01) 28 (12.7) 9.4 (3.7-24.3)
CVD: Cardiovascular disease; 10-year ASCVD risk in percentage (%). *1p value for comparison 10-year. ASCVD between sub-group using Mann-Whitney test  and Kruskal-
Wallis test for the variables with 2 sub-groups and >2 sub-groups respectively; the lowest value in the sub-group as a control group. *2Spearman’s rho correlation: 10-year 
ASCVD risk with the variables. *3OR (95% CI): odds ratio (95% confidence interval); the lowest cut point in the sub-group as a control group. ASCVD: Atherosclerotic 
cardiovascular disease, HDL-C: High-density lipoprotein-cholesterol, LDL-C: Low-density lipoprotein-cholesterol, Total-C: Total-cholesterol, SD: Standard deviation
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subjects [11]. After 3 years of PCE launching, a study suggested to 
recalibrate the PCE [25]. While one cohort in Europe preferred the 
ASCVD risk than SCORE from ESC/EAS guidelines due to the method 
had higher sensitivity and specificity for the eligibility for statin [20]. 
The ASCVD risk predicted from this study needs further investigation 
and comparison with the actual ASCVD risk observed among the 
Sleman District population.
Limitation
There were 15 subjects missed in the study because the ASCVD risk 
method could not cover the <40-year subjects. The sub-groups of 
gender, hypertension treatment, DM, and the lipid profiles had the 
different proportion in each sub-group because the study included 
all eligible subjects without matching the subjects in each group. The 
ASCVD risk from PCE was known to underestimate or overestimate 
the 10-year ASCVD risk for subjects from other than white and African 
American races, though the ASCVD risk model was likely give a better 
prediction in general population.
CONCLUSIONS
The 10-year ASCVD risk prediction of the subjects using the PCE method 
had the median score at 4.4 (0.2-41.4), and the score was classified as 
low-risk of ASCVD. The ASCVD risk had the significant association with 
non-lipid profiles, total-C, and ratio total-C/HDL-C, triglyceride/HDL-C, 
and LDL-C/HDL-C.
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